AHR and neoplasm: This activates the aryl hydrocarbon receptor (AHR), resulting in upregulation of immunosuppressive mediators including IL-10, TGF-β, and SIGLEC15, ultimately promoting tumor immune evasion and immunotherapy resistance.230